Skip to main content

Table 2 Details of patient characteristics, results of each PET imaging, and reference criteria for the final diagnosis in patients with non-glioma tumors and non-neoplastic lesions

From: Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma

Pt. No. Age range (y) Locationa FDG NH3 MET Method of diagnosis Final diagnosis
Visual L/WMb Visual L/WM Visual L/WM
Non-glioma tumors
 1 50–55 Cerebellum (+) 2.24 (+) 1.72 (+) 2.89 Operation Metastatic adenocarcinoma
 2 20–25 L. basal ganglia region (−) 1.32 (+) 2.67 (+) 3.24 Biopsy Germinoma
 3 35–40 R. cavernous sinus area (+) 2.38 (+) 2.30 (+) 3.35 Operation Squamous cell carcinoma
 4 40–45 Suprasellar (−) 1.07 (+) 2.42 (+) 2.28 Operation Craniopharyngioma
 5 65–70 R. parietal (−) 1.37 (+) 3.75 (+) 2.72 Operation Meningioma
 6 60–65 Cerebellum (−) 1.28 (+) 3.66 (+) 2.78 Operation Hemangioblastoma
 7 25–30 Cerebellum (+) 2.61 (+) 2.00 (+) 2.00 Operation Medulloblastoma
 8 25–30 Cerebellum (+) 2.32 (+) 2.40 (+) 2.24 Operation Medulloblastoma
 9 45–50 L. frontal (+) 4.02 (+) 3.09 (+) 3.00 Operation Metastatic tumor
 10 30–35 R. frontal (−) 1.22 (−) 1.60 (+−) 1.51 Operation DNT
Non-neoplastic lesions
 11 20–25 L. frontal (+) 2.75 (+−) 1.68 (+−) 1.58 Follow-up Inflammation
 12 40–45 L. frontal-parietal (−) 1.76 (−) 1.10 (−) 1.00 Biopsy Demyelination
 13 30–35 R. parietal (+−) 2.10 (+−) 1.64 (+) 2.27 Follow-up Demyelination
 14 25–30 R. basal ganglia region (+−) 2.12 (+−) 1.72 (+−) 1.50 Biopsy Demyelination
 15 70–75 Cervical spinal (+) 2.88 (+−) 1.70 (+−) 1.78 Follow-up Inflammation
 16 20–25 R. cerebellopontine angle (−) 1.32 (+−) 1.63 (+−) 1.55 Follow-up Demyelination
 17 25–30 R. thalamus (−) 1.80 (+−) 1.75 (+−) 1.77 Follow-up Inflammation
 18 40–45 R. parietal (+) 2.23 (+−) 1.72 (+) 2.49 Biopsy Inflammation
 19 35–40 R. cerebellum (+) 2.80 (−) 1.45 (−) 1.38 Follow-up Inflammation
 20 40–45 Brain stem, R. temporal (−) 1.58 (−) 1.55 (+−) 1.54 Follow-up Inflammation
 21 40–45 L. pons (−) 1.56 (−) 1.29 (−) 1.31 Follow-up Infarction
 22 50–55 L. temporal (+) 2.49 (−) 0.94 (+) 2.67 Operation Brain abscess
 23 45–50 L. parietal (+) 3.28 (−) 1.63 (+) 2.88 Operation Brain abscess
 24 40–45 R. frontal (+) 3.80 (−) 1.58 (+) 3.04 Operation Brain abscess
 25 20–25 L. parietal (−) 1.10 (−) 1.18 (−) 1.32 Biopsy Demyelination
 26 30–35 L. basal ganglia region (−) 1.44 (−) 1.45 (−) 1.40 Follow-up Multiple sclerosis
 27 40–45 R. cerebellum (−) 1.98 (+−) 1.79 (+) 2.60 Follow-up Infarction
 28 50–55 L. frontal (+−) 2.10 (+−) 1.75 (+) 1.95 Biopsy Inflammation
 29 78–80 R. parietal (−) 1.06 (−) 1.14 (+) 1.86 Follow-up Hemorrhage
 30 40–45 L. frontal and parietal (+) 2.70 (+) 1.87 (+) 3.15 Biopsy Inflammation
 31 40–45 Pons (−) 1.68 (−) 1.54 (−) 1.38 Follow-up Brain abscess
 32 50–55 R. basal ganglia region (−) 1.58 (−) 1.02 (+) 1.81 Follow-up Infarction
 33 25–30 L. thalamus (−) 1.52 (−) 1.44 (−) 1.15 Biopsy Demyelination
  1. a R right, L left, b L/WM Lesion-to-white matte ratio, DNT dysembryoplastic neuroepithelial tumor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us